Notably, whether ADAM15 serves as a specific biomarker for IPF or is broadly present in patients with various ILD subtypes, as well as which specific ILD subtypes (excluding IPF and sarcoidosis) CDH15 may target, remains to be determined through the discovery of more detailed GWAS datasets for ILD subtypes. This evidence concerns the gene CDH15 and interstitial lung disease.